Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 300

1.
2.

Vinorelbine and cisplatin in advanced squamous cell carcinoma of the cervix: the South African experience.

Goedhals L, Falkson G, Smith BL, Falkson CI, Gasmi J, Lategan A, Burillon JP, His P.

Anticancer Res. 2005 May-Jun;25(3c):2489-92.

3.

Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.

Weiss RB, Woolf SH, Demakos E, Holland JF, Berry DA, Falkson G, Cirrincione CT, Robbins A, Bothun S, Henderson IC, Norton L; Cancer and Leukemia Group B.

J Clin Oncol. 2003 May 1;21(9):1825-35. Erratum in: J Clin Oncol. 2003 Dec 1;21(23):4469.

PMID:
12721260
4.

Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer.

Buzdar A, Hayes D, El-Khoudary A, Yan S, Lønning P, Lichinitser M, Gopal R, Falkson G, Pritchard K, Lipton A, Wolter K, Lee A, Fly K, Chew R, Alderdice M, Burke K, Eisenber P; Droloxifene 301 Study Group.

Breast Cancer Res Treat. 2002 May;73(2):161-75.

PMID:
12088118
5.

Prevalence and management of cancer pain in South Africa.

Beck SL, Falkson G.

Pain. 2001 Oct;94(1):75-84.

PMID:
11576747
6.

Development of three African language translations of the FACT-G.

Mullin V, Cella D, Chang CH, Eremenco S, Mertz M, Lent L, Falkson C, Falkson G.

Qual Life Res. 2000 Mar;9(2):139-49.

PMID:
10983478
7.

Dose-dependent hormonal effects of toremifene in postmenopausal breast cancer patients.

Ellmén J, Werner D, Hakulinen P, Keiling R, Fargeot P, Falkson G, Bezwoda WR.

Cancer Chemother Pharmacol. 2000;45(5):402-8.

PMID:
10803924
8.
9.

Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group.

Recht A, Gray R, Davidson NE, Fowble BL, Solin LJ, Cummings FJ, Falkson G, Falkson HC, Taylor SG 4th, Tormey DC.

J Clin Oncol. 1999 Jun;17(6):1689-700.

PMID:
10561205
10.
11.

Morphology and other prognostic factors of hepatocellular carcinoma.

Chedid A, Ryan LM, Dayal Y, Wolf BC, Falkson G.

Arch Pathol Lab Med. 1999 Jun;123(6):524-8.

PMID:
10383806
12.

Hepatocellular carcinoma.

Falkson G, Falkson CI, Garbers LM.

Cancer Treat Res. 1998;98:83-109. Review. No abstract available.

PMID:
10326666
13.

Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis--an intergroup study.

Mansour EG, Gray R, Shatila AH, Tormey DC, Cooper MR, Osborne CK, Falkson G.

J Clin Oncol. 1998 Nov;16(11):3486-92.

PMID:
9817265
14.
15.

Fadrozole versus megestrol acetate: a double-blind randomised trial in advanced breast cancer.

Bezwoda WR, Gudgeon A, Falkson G, Jordaan JP, Goedhals L.

Oncology. 1998 Sep-Oct;55(5):416-20.

PMID:
9732218
16.

Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment.

Falkson G, Gelman RS, Pandya KJ, Osborne CK, Tormey D, Cummings FJ, Sledge GW, Abeloff MD.

J Clin Oncol. 1998 May;16(5):1669-76.

PMID:
9586877
17.
18.

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.

Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffmann W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U, Trunet PF.

J Clin Oncol. 1998 Feb;16(2):453-61.

PMID:
9469328
19.

The low-grade lymphoproliferative disorders.

Eek R, Falkson G.

Oncology. 1997 Nov-Dec;54(6):441-58. Review.

PMID:
9394840
20.

Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer.

Ribeiro M, Ruff P, Falkson G.

Am J Clin Oncol. 1997 Dec;20(6):605-8.

PMID:
9391550
21.

The role of radiotherapy in the management of operable locally advanced breast carcinoma: results of a randomized trial by the Eastern Cooperative Oncology Group.

Olson JE, Neuberg D, Pandya KJ, Richter MP, Solin LJ, Gilchrist KW, Tormey DC, Veeder M, Falkson G.

Cancer. 1997 Mar 15;79(6):1138-49.

PMID:
9070491
23.

A phase II trial of fludarabine in patients with previously treated chronic lymphocytic leukaemia.

Hocepied AM, Falkson CI, Falkson G.

S Afr Med J. 1996 May;86(5):549-50.

PMID:
8711555
24.

13-Cis-retinoic acid and interferon alpha-2a in patients with advanced esophageal cancer: a phase II trial.

Slabber CF, Falkson G, Burger W, Schoeman L.

Invest New Drugs. 1996;14(4):391-4.

PMID:
9157075
25.

Hepatocellular carcinoma. An ECOG randomized phase II study of beta-interferon and menogaril.

Falkson G, Lipsitz S, Borden E, Simson I, Haller D.

Am J Clin Oncol. 1995 Aug;18(4):287-92.

PMID:
7625367
26.

Ten-year follow-up study of premenopausal women with metastatic breast cancer: an Eastern Cooperative Oncology Group study.

Falkson G, Holcroft C, Gelman RS, Tormey DC, Wolter JM, Cummings FJ.

J Clin Oncol. 1995 Jun;13(6):1453-8.

PMID:
7751892
27.

A phase II trial of vindesine in hepatocellular cancer.

Falkson G, Burger W.

Oncology. 1995 Jan-Feb;52(1):86-7.

PMID:
7800350
28.

Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: a dose-ranging study.

Bleiberg HH, Spielmann M, Falkson G, Romain D.

Clin Ther. 1995 Jan-Feb;17(1):38-51.

PMID:
7758060
29.

Small cell lung cancer: analysis of factors influencing the response to treatment and survival.

de Wet M, Falkson G, Rapoport BL.

Oncology. 1994 Nov-Dec;51(6):523-34.

PMID:
7970498
30.

Recombinant human erythropoietin in the treatment of cancer-related anaemia.

Falkson CI, Keren-Rosenberg S, Uys A, Falkson G, Stevens K, Vermaak WJ.

Oncology. 1994 Nov-Dec;51(6):497-501.

PMID:
7970493
31.

Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.

Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA.

J Clin Oncol. 1994 Aug;12(8):1535-40.

PMID:
8040664
32.

Myelodysplastic syndrome and acute myeloid leukemia secondary to mitolactol treatment in patients with breast cancer.

Bennett JM, Troxel AB, Gelman R, Falkson G, Coccia-Portugal MD, Dreicer R, Tormey DC, Rushing D.

J Clin Oncol. 1994 Apr;12(4):874-5. No abstract available.

PMID:
8151329
33.

Reinduction with the same cytostatic treatment in patients with metastatic breast cancer: an Eastern Cooperative Oncology Group study.

Falkson G, Gelman R, Glick J, Falkson CI, Harris J.

J Clin Oncol. 1994 Jan;12(1):45-9.

PMID:
8270982
34.

FIVB plus GM-CSF in metastatic colorectal cancer.

Falkson CI, Falkson G, Falkson HC, Uys A, Keren-Rosenberg S.

Invest New Drugs. 1994;12(1):49-52.

PMID:
7960606
35.

Phase II trial of fotemustine in patients with metastatic malignant melanoma.

Falkson CI, Falkson G, Falkson HC.

Invest New Drugs. 1994;12(3):251-4.

PMID:
7896545
36.

Survival determinants in patients with advanced ovarian cancer.

Ansell SM, Rapoport BL, Falkson G, Raats JI, Moeken CM.

Gynecol Oncol. 1993 Aug;50(2):215-20.

PMID:
8375737
37.

Suramin in combination with mitomycin C in hormone-resistant prostate cancer. A phase II clinical study.

Rapoport BL, Falkson G, Raats JI, de Wet M, Lotz BP, Potgieter HC.

Ann Oncol. 1993 Aug;4(7):567-73.

PMID:
8363988
38.

Combined modality treatment of gastrointestinal cancer.

Falkson G, Falkson CI, Falkson CB.

Curr Opin Oncol. 1993 Jul;5(4):710-8. Review.

PMID:
8364089
39.

The value of radiotherapy or chemotherapy after intubation for advanced esophageal carcinoma--a prospective randomized trial.

Schmid EU, Alberts AS, Greeff F, Terblanche AP, Schoeman L, Burger W, Shiels RA, Friediger D, Van der Hoven A, Falkson G.

Radiother Oncol. 1993 Jul;28(1):27-30.

PMID:
7694321
40.

Repeated use of granisetron in patients receiving cytostatic agents.

de Wet M, Falkson G, Rapoport BL.

Cancer. 1993 Jun 15;71(12):4043-9.

PMID:
8389659
41.

Postmenopausal breast cancer. Drug therapy in the 1990s.

Falkson CI, Falkson G, Falkson HC.

Drugs Aging. 1993 Mar-Apr;3(2):106-21. Review.

PMID:
8477145
42.

A phase II trial of a chemotherapy combination in elderly patients with aggressive lymphoma.

Ansell SM, Falkson G.

Ann Oncol. 1993 Feb;4(2):172. No abstract available.

PMID:
8448086
43.
44.

Maintenance tamoxifen after induction postoperative chemotherapy in node-positive breast cancer patients: the Eastern Cooperative Oncology Group Trials.

Tormey DC, Gray R, Falkson HC, Gilchrist K, Abeloff MD, Falkson G.

Recent Results Cancer Res. 1993;127:185-96. No abstract available.

PMID:
8502815
45.

Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long-term follow-up and causes of death.

Cummings FJ, Gray R, Tormey DC, Davis TE, Volk H, Harris J, Falkson G, Bennett JM.

J Clin Oncol. 1993 Jan;11(1):29-35.

PMID:
8418238
46.

Leukemia after chemotherapy for cancer.

Chasen MR, Falkson G.

Cancer Biother. 1993 Summer;8(2):115-22. Review. No abstract available.

PMID:
7804352
47.

Ondansetron in a patient with porphyria.

De Wet M, Jooste R, Coccia-Portugal MA, Falkson G.

S Afr Med J. 1992 Dec;82(6):480. No abstract available.

PMID:
1465703
48.

Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: an Eastern Cooperative Oncology Group trial.

Tormey DC, Gray R, Abeloff MD, Roseman DL, Gilchrist KW, Barylak EJ, Stott P, Falkson G.

J Clin Oncol. 1992 Dec;10(12):1848-56.

PMID:
1453199
50.

[Intraperitoneal recombinant gamma interferon (RU 42369) efficacy in ovarian carcinomas. European BRM Study Group].

Guastalla JP, Pujade-Lauraine E, Colombo N, Namer N, Fumoleau P, Monnier A, Nooy MA, Falkson G, Mignot L, Bugat R, et al.

Pathol Biol (Paris). 1992 Nov;39(9):831-2. French. No abstract available.

PMID:
1538893

Supplemental Content

Loading ...
Support Center